News | September 09, 2014

TCT 2014 Late-breaking Trials and First Report Investigations

Transcatheter Cardiovascular Therapeutics (TCT) has announced the late-breaking trial presentations at TCT 2014, Sept. 13-17.
 
Late-breaking clinical trials are typically first-time international or U.S. presentations of the primary endpoint or important secondary endpoint results of prospective, randomized clinical trials or presentations of large-scale, impactful single-center or multicenter registries. A first-report investigation is a smaller randomized trial, novel science, or early-human investigation.
 
All presentations will take place in the Main Arena area in the ballroom on level 3.
 
 
Saturday, Sept. 12 — Main Arena I
 
• 11 a.m.— PARTNER I: Five-Year Results From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Balloon-Expandable Device Versus Conservative Care in Extremely High-Risk Patients with Aortic Stenosis. Presented by Samir R. Kapadia.
 
• 11:24 a.m. — U.S. CoreValve High Risk Trial: Cost-Effectiveness Analysis From a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement with a Self-Expanding Device Versus Surgical Aortic Valve Replacement in High-Risk Patients with Aortic Stenosis. Presented by Matthew R. Reynolds. 
 
• 11:42 a.m. — CLEAN-TAVI: A Prospective, Randomized Trial of Cerebral Embolic Protection in High-Risk Patients with Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. Presented by Axel Linke. 
 
• Noon — The CoreValve US Pivotal Trial: Two-Year Results with a Self-Expanding Bioprosthesis in Extremely High-Risk Patients with Aortic Stenosis. Presented by Steven J. Yakubov.
 
• 12:15 p.m. — ISAR-CLOSURE: A Prospective, Randomized Trial of Two Vascular Closure Devices Versus Manual Compression After Femoral Artery Access. Presented by Stefanie Schulz. 
 
Sunday, Sept. 14 — Main Arena II
 
• 11 a.m. — ABSORB II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus an Everolimus-Eluting Metallic Stent in Patients with Coronary Artery Disease. Presented by Patrick W. Serruys.
 
• 11:24 a.m. — DKCRUSH-VI: A Prospective, Randomized Trial of FFR-Guided Versus Angiography-Guided Provisional T-Stenting in Patients with True Coronary Bifurcation Lesions. Presented by Shao Liang Chen. 
 
• 11:42 a.m. — RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents. Presented by Fernando Alfonso.
 
Noon — IVUS-CTO: A Prospective, Randomized Trial of Intravascular Ultrasound-Guided Versus Angiography-Guided Drug-Eluting Stent Intervention in Coronary Chronic Total Occlusions. Presented by Yang-Soo Jang.
 
• 12:15 p.m. — OCT STEMI: A Prospective, Randomized Trial of Optical Coherence Tomography Guidance During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Presented by Pavel Cervinka. 
 
 
Monday, Sept. 15 — Main Arena III
 
• 11:10 a.m. — BRIGHT: A Prospective, Randomized Trial of Bivalirudin Monotherapy Versus Heparin Monotherapy Versus Heparin Plus Tirofiban in Patients with Acute Myocardial Infarction Undergoing Coronary Intervention. Presented by Yaling Han.
 
• 11:30 a.m. — ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by Nikolaus Sarafoff. 
 
• 11:48 a.m. — SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation. Presented by
Antonio Colombo. 
 
• 12:06 p.m. — TRANSLATE-ACS: A Large-Scale Registry Comparing Patterns of Use and One-Year Outcomes with Prasugrel Versus Clopidogrel in Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention. . Presented by Tracy Y. Wang. 
 
• 12:21 p.m. — VELOCITY: A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Presented by Gregg W. Stone. 
 
 
Tuesday, Sept. 16 — Main Arena IV
 
• 11 a.m. — PRIMA: A Prospective, Randomized Trial of PFO Closure in Patients with Refractory Migraine with Aura. Presented by David Hildick-Smith.
 
• 11:24a.m. — Symplicity Flex: A Prospective, Randomized, Sham-Controlled Trial of Renal Sympathetic Denervation in Patients with Mild Refractory Hypertension. . Presented by Steffen Desch
 
• 11:42 a.m. — EXCITE ISR: A Prospective, Randomized Trial of Excimer Laser Atherectomy Versus Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis.  Presented by Eric J. Dippel. 
 
Noon — I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease. Presented by Bo Xu.
 
• 12:15 p.m. — EVERBIO II: A Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting and Biolimus-Eluting Metallic Stents in Patients with Coronary Artery Disease. Presented by Stephane Cook.
 

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init